Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.48 |
| ▸ | RXRA | P19793 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | DTYMK | P23919 | 1/20 | 0.38 |
| ▸ | HSPA1A | P0DMV8 | 1/20 | 0.37 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.37 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.35 |
| ▸ | CASP6 | P55212 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | FBP1 | P09467 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL196344 | 1.00 | TSHR (0.48) | TSHRRXRATDP1L3MBTL1DTYMK | |
| SCHEMBL5231767 | 0.90 | TSHR (0.48) | TSHRRXRATDP1L3MBTL1DTYMK | |
| SCHEMBL6214961 | 0.79 | TSHR (0.57) | TSHRRXRATDP1L3MBTL1DTYMK | |
| SCHEMBL58249 | 0.78 | KMT2A (0.34) | TSHRTDP1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL28853079 | 0.78 | KMT2A (0.34) | TSHRTDP1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL28853081 | 0.78 | KMT2A (0.34) | TSHRTDP1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL216109 | 0.75 | CYP1A2 (0.39) | TSHRTDP1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL6304256 | 0.73 | TSHR (0.71) | TSHRTDP1L3MBTL1DTYMKSMN1; SMN2 | |
| SCHEMBL28842429 | 0.72 | TSHR (0.69) | TSHRTDP1L3MBTL1DTYMKSMN1; SMN2 | |
| SCHEMBL28194741 | 0.72 | TSHR (0.69) | TSHRTDP1L3MBTL1DTYMKSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7511046-B2 | Thienoisoxazolyl- and thienylpyrrazolyl-phenoxy substituted propyl derivatives useful as D4 antagonists | AVENTIS HOKLINGS INC. (US) | 2009-03-31 | — | — | US | disclosed |
| US-7235559-B1 | Therapeutic quinazoline derivatives | ASTRAZENECA AB (SE) | 2007-06-26 | — | — | US | disclosed |
| US-20070004695-A1 | THIENOISOXAZOLYL-AND THIENYLPYRRAZOLYL PHENOXY SUBSTITUTED PROPYL DERIVATIVES USEFUL AS D4 ANTAGONISTS | AVENTIS PHARMACEUTICALS INC. (US) | 2007-01-04 | — | — | US | disclosed |
| US-7125903-B1 | Thienoisoxazolyl-and thienylpyrrazolyl-phenoxy substituted propyl derivatives useful as D4 antagonists | AVENTIS PHARMACEUTICALS INC. (US) | 2006-10-24 | — | — | US | disclosed |
| EP-1216250-B1 | THIENOISOXAZOLYL AND THIENYLPYRRAZOLYL PHENOXY SUBSTITUTED PROPYL DERIVATIVES USEFUL AS D4 ANTAGONISTS | AVENTIS PHARMA INC (US) | 2003-11-19 | — | — | EP | disclosed |
| EP-1218355-A1 | THERAPEUTIC QUINAZOLINE DERIVATIVES | AstraZeneca AB (SE) | 2002-07-03 | — | — | EP | disclosed |
| EP-1216250-A1 | THIENOISOXAZOLYL AND THIENYLPYRRAZOLYL PHENOXY SUBSTITUTED PROPYL DERIVATIVES USEFUL AS D4 ANTAGONISTS | Aventis Pharmaceuticals Inc. (US) | 2002-06-26 | — | — | EP | disclosed |
| WO-2001021597-A1 | THERAPEUTIC QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2001-03-29 | — | — | WO | disclosed |
| WO-2001019833-A1 | THIENOISOXAZOLYL- AND THIENYLPYRRAZOLYL-PHENOXY SUBSTITUTED PROPYL DERIVATIVES USEFUL AS D4 ANTAGONISTS | AVENTIS PHARMACEUTICALS, INC. (US) | 2001-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004695-A1 | THIENOISOXAZOLYL-AND THIENYLPYRRAZOLYL PHENOXY SUBSTITUTED PROPYL DERIVATIVES USEFUL AS D4 ANTAGONISTS | DRD4, DRD2, SLC6A3 | TSHR 106/4885RXRA 858/4885TDP1 259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.